Cell adhesion molecules and immunotherapy in advanced non-small cell lung cancer: Current process and potential application.

Front Oncol · 2023 · PMC9989313 · PMID 36895477

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

nominally significantno p-value reported

Whether anti-PD-1 or anti-PD-L1 antibodies has less adverse events remains controversial and studies showed contradictory outcomes ( 17 , 162 – 164 ) A study showed that HLADRB1*11:01 and pruritus as well as a nominally significant additive association between HLA-DQB1*03:01 and colitis, indicating the role of genetic diversity in adverse events of immune checkpoint inhibitors ( 165 ).

also in 7,732 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.